IL155962A0 - Compounds specific to adenosine a1, a2a, and a3 receptors and uses thereof - Google Patents
Compounds specific to adenosine a1, a2a, and a3 receptors and uses thereofInfo
- Publication number
- IL155962A0 IL155962A0 IL15596201A IL15596201A IL155962A0 IL 155962 A0 IL155962 A0 IL 155962A0 IL 15596201 A IL15596201 A IL 15596201A IL 15596201 A IL15596201 A IL 15596201A IL 155962 A0 IL155962 A0 IL 155962A0
- Authority
- IL
- Israel
- Prior art keywords
- adenosine
- receptors
- compounds specific
- compounds
- specific
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
| US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
| PCT/US2001/045280 WO2002057267A1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL155962A0 true IL155962A0 (en) | 2003-12-23 |
Family
ID=27419112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15596201A IL155962A0 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptors and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1347980A4 (cs) |
| JP (1) | JP4579497B2 (cs) |
| CN (1) | CN1263757C (cs) |
| AP (1) | AP1893A (cs) |
| AU (1) | AU2002248151B2 (cs) |
| BR (1) | BR0115847A (cs) |
| CA (1) | CA2430577A1 (cs) |
| CZ (1) | CZ20031831A3 (cs) |
| EA (1) | EA007254B1 (cs) |
| HU (1) | HUP0400692A3 (cs) |
| IL (1) | IL155962A0 (cs) |
| ME (1) | MEP35308A (cs) |
| MX (1) | MXPA03004717A (cs) |
| NO (1) | NO327207B1 (cs) |
| NZ (1) | NZ525885A (cs) |
| OA (1) | OA13295A (cs) |
| PL (1) | PL363245A1 (cs) |
| WO (1) | WO2002057267A1 (cs) |
| YU (1) | YU42703A (cs) |
| ZA (1) | ZA200303729B (cs) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
| EA003604B1 (ru) | 1998-06-02 | 2003-06-26 | Оси Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ ПИРРОЛО [2,3d] ПИРИМИДИНОВ И ИХ ПРИМЕНЕНИЕ |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
| JP2005529062A (ja) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンａ１及びａ３受容体に特異的な化合物とその使用 |
| MXPA04005510A (es) * | 2001-12-07 | 2006-02-24 | Vertex Pharma | Compuestos basados en pirimidina utiles como inhibidores de gsk-3. |
| CN1816551A (zh) | 2001-12-20 | 2006-08-09 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途 |
| AU2002366811B2 (en) | 2001-12-20 | 2009-01-15 | Osi Pharmaceuticals, Inc. | Pyrimidine A2B selective antagonist compounds, their synthesis and use |
| US7199119B2 (en) * | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| ES2344800T3 (es) * | 2005-02-18 | 2010-09-07 | Solvay Pharmaceuticals Gmbh | Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema productor de endotelina endogena y diureticos. |
| EP3421471B1 (en) | 2006-04-25 | 2021-05-26 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| MX2010007523A (es) | 2008-01-11 | 2010-08-18 | Natco Pharma Ltd | Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer. |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| JP6080837B2 (ja) | 2011-04-01 | 2017-02-15 | アストラゼネカ アクチボラグ | 療法的治療 |
| PL2785349T5 (pl) | 2011-11-30 | 2023-01-30 | Astrazeneca Ab | Kombinacja do leczenia nowotworu |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| RU2014151004A (ru) * | 2012-06-07 | 2016-08-10 | Ф. Хоффманн-Ля Рош Аг | Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы |
| NZ754629A (en) | 2013-06-21 | 2021-07-30 | Zenith Epigenetics Ltd | Novel bicyclic bromodomain inhibitors |
| EP3010917B1 (en) * | 2013-06-21 | 2018-01-31 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| WO2016087942A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridines as bromodomain inhibitors |
| HK1245248B (en) | 2014-12-11 | 2020-05-15 | 恒翼生物医药(上海)股份有限公司 | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| MX380276B (es) * | 2015-01-20 | 2025-03-12 | Wuxy Fortune Pharmaceutical Co Ltd | Inhibidor jak. |
| CN107531695B (zh) | 2015-04-29 | 2020-03-27 | 无锡福祈制药有限公司 | Jak抑制剂 |
| US10174056B2 (en) | 2015-05-29 | 2019-01-08 | Wuxi Fortune Pharmaceutical Co., Ltd | Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CN105771672B (zh) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法 |
| EP3594216B1 (en) * | 2017-03-07 | 2022-04-06 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof |
| CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
| CN118834214A (zh) * | 2018-06-04 | 2024-10-25 | 爱克思科技有限公司 | 作为腺苷受体拮抗剂的吡唑并嘧啶化合物 |
| CN110128316B (zh) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | 5位取代的β-脯氨酸及其衍生物的制备方法 |
| CN110272373B (zh) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | 一种具有选择性的腺苷a1受体拮抗剂及其应用 |
| CN114085178A (zh) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013676A1 (en) * | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Pyrrolopyrimidines as crf antagonists |
| US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| EA003604B1 (ru) * | 1998-06-02 | 2003-06-26 | Оси Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ ПИРРОЛО [2,3d] ПИРИМИДИНОВ И ИХ ПРИМЕНЕНИЕ |
| PT1246623E (pt) * | 1999-12-02 | 2006-12-29 | Osi Pharm Inc | Compostos específicos para o receptor de adenosina a1,a2a e a3 e as suas utilizações |
| JP2005529062A (ja) * | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンａ１及びａ３受容体に特異的な化合物とその使用 |
-
2001
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1489590A (zh) | 2004-04-14 |
| JP4579497B2 (ja) | 2010-11-10 |
| AU2002248151B2 (en) | 2008-02-21 |
| CN1263757C (zh) | 2006-07-12 |
| EA007254B1 (ru) | 2006-08-25 |
| PL363245A1 (en) | 2004-11-15 |
| EA200300628A1 (ru) | 2003-12-25 |
| NO327207B1 (no) | 2009-05-11 |
| MXPA03004717A (es) | 2004-06-30 |
| NO20032482L (no) | 2003-07-28 |
| HUP0400692A3 (en) | 2007-09-28 |
| EP1347980A1 (en) | 2003-10-01 |
| WO2002057267A1 (en) | 2002-07-25 |
| OA13295A (en) | 2007-04-13 |
| JP2004517896A (ja) | 2004-06-17 |
| EP1347980A4 (en) | 2005-02-09 |
| MEP35308A (en) | 2011-02-10 |
| NZ525885A (en) | 2005-01-28 |
| HUP0400692A2 (hu) | 2004-07-28 |
| BR0115847A (pt) | 2004-02-25 |
| YU42703A (sh) | 2006-03-03 |
| AP1893A (en) | 2008-09-23 |
| ZA200303729B (en) | 2004-05-14 |
| AP2003002807A0 (en) | 2003-06-30 |
| CZ20031831A3 (cs) | 2004-05-12 |
| CA2430577A1 (en) | 2002-07-25 |
| NO20032482D0 (no) | 2003-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL155962A0 (en) | Compounds specific to adenosine a1, a2a, and a3 receptors and uses thereof | |
| IL152726A0 (en) | Adenosine a2a receptor antagonists | |
| GC0000287A (en) | Purine derivatives | |
| PL366038A1 (en) | Nucleoside compounds and uses thereof | |
| IL150543A0 (en) | Purine derivatives | |
| GB0022695D0 (en) | Purine Derivatives | |
| PL353969A1 (en) | Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands | |
| IL152529A0 (en) | Purine derivatives | |
| EP1287154A4 (en) | NUCLEOTIDES WITH CHARGE SWITCHING | |
| PL365607A1 (en) | High-strength, stabilized absorbent article | |
| IL156046A0 (en) | Condensed purine derivatives as a1 adenosine receptor antagonists | |
| AU6807501A (en) | 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | |
| AU3860101A (en) | Utility lighter | |
| AU3167402A (en) | Aminotriazolopyridiine derivatives as adenosine receptor ligands | |
| GB0028814D0 (en) | Improvements relating to biosorbtion | |
| HK1058933A (en) | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof | |
| SI1246623T1 (sl) | Spojine, specificne za adenozin A1, A2a in A3 receptor, in njihove uporabe | |
| GB2363331B (en) | Supplement to enhance fertility | |
| ZA200204153B (en) | Compounds specific to adenosine A3, A2A, and A3 receptor and uses thereof. | |
| GB0013038D0 (en) | Improvements relating to bicycles | |
| HRPK20000420B1 (en) | Purine l-nucleosides, analogs and uses thereof | |
| HRPK20000422B1 (en) | Purine l-nucleosides, analogs and uses thereof | |
| GB0018246D0 (en) | Purine derivatives | |
| GB0004764D0 (en) | Improvements in, or relating to, aerofoils | |
| GB0021285D0 (en) | Nucleoside derivatives |